Back to Questions
Question ID: WS-53
Submitted by: Deadly Cancer Coalition
February 8, 2011
Comments
Question ID: WS-53
Submitted by: Deadly Cancer Coalition
February 8, 2011
Question: Can we optimize the early translation of available and newly-discovered genetic, molecular, and proteomic information to the individualization of therapy? Background: Molecular classifications are critical to identify targets and enhance drug discovery. Once the pathways that drive and sustain a tumor are identified, then it can be determined whether they are therapeutically targetable. Additionally, genetic analyses can reveal which patients can benefit most from novel or currently available therapies, allowing a strategic and careful selection of personalized treatment regimens and clinical trials.
| This question has not yet been evaluated by users |
Comments
